Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug363 | Assessment of Dietary Changes in Adults in the Quarantine Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D055370 | Lung Injury NIH | 0.19 |
| D014947 | Wounds and Injuries NIH | 0.17 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Existing information suggests that a drug called heparin, given through a device called a nebuliser, will decrease severity of lung damage caused by COVID-19 who require the assistance of a ventilator to breathe. It is thought that heparin could do this through multiple mechanisms. The investigators will measure the effect with a marker called d-dimer, which is related to blood clotting, and monitor the safety of this treatment as one of the major outcomes for the study. The investigators will also assess clinical outcomes such as markers of oxygen levels, time to liberation from a ventilator in patients with COVID-19 lung disease, and functional outcomes at day 28 and 60 as secondary outcomes.
Description: Effect of nebulised heparin on d-dimer profile, assessed via d-dimer AUC and via a mixed effects model, with data collected on days 1, 3, 5 and 10.
Measure: D-dimer profile Time: Up to day 10.Description: Safety of nebulised heparin delivered by aerogen solo nebuliser in patients with COVID-19 induced severe respiratory failure, as measured by the incidence of severe adverse events.
Measure: Frequenccy of Severe Adverse Outcomes Time: Up to day 60Description: Determine the impact of nebulised heparin on oxygenation index
Measure: Oxygenation Index Time: Up to day 10Description: Effect of nebulised heparin on indices of inflammation (Interleukin (IL)-1β, IL-6, IL-8, IL-10 and soluble TNF receptor 1 (sTNFR1), C-reactive protein, procalcitonin, Ferritin,) will be assessed (AUC on days 1, 3, 5 and 10)
Measure: Indices of Inflammation Time: Up to day 10Description: Effect of nebulised heparin on the ratios of IL-1β/IL-10 and IL-6/IL-10 will also be assessed.
Measure: Ratios of Indices of Inflammation Time: Up to day 10Description: Effect of nebulised heparin on other indices of coagulation (Fibrinogen; lactate dehydrogenase) will be assessed (AUC on days 1, 3, 5 and 10).
Measure: Indices of Coagulation Time: Up to day 10Description: Determine the effect of nebulised heparin on Quasi-Static Lung Compliance (i.e. tidal volume/(Plateau pressure-PEEP) measured on days 1,3,5,10.
Measure: Quasi-Static Lung Compliance Time: Up to day 10Description: Time to separation from invasive ventilation, where non survivors are treated as though not separated from invasive ventilation.
Measure: Time to separation from invasive ventilation Time: Up to day 28Description: Number treated with neuromuscular blockers instituted after enrolment
Measure: Number treated with neuromuscular blockers Time: Up to day 10Description: Number treated with prone positioning instituted after enrolment
Measure: Number treated with Prone positioning Time: Up to day 10Description: Number treated with extra-corporeal membrane oxygenation instituted after enrolment
Measure: Number treated with extra-corporeal membrane oxygenation Time: Up to day 10Description: Number tracheotomised
Measure: Number requiring Tracheostomy Time: Up to day 28Description: Time to separation from invasive ventilation among survivors
Measure: Time to separation from invasive ventilation among survivors Time: Up to day 28Description: Time to separation from the ICU to day 28, where non-survivors to day 28 are treated as though not separated from invasive care
Measure: Discharge to ward Time: Up to day 28Description: Time to discharge from the ICU to day 28, among survivors
Measure: Discharge to ward in survivors Time: Up to day 28Description: Survival to day 28; Survival to day 60; and Survival to hospital discharge, censored at day 60
Measure: Patient Survival Time: Up to day 60Description: Number residing at home or in a community setting at day 60
Measure: Number of patients residing at home or in a community setting at day 60 Time: Up to day 60Description: Number residing at home or in a community setting at day 60, among survivors
Measure: Number of surviving patients residing at home or in a community Time: Up to day 60Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports